Literature DB >> 16009605

Determination of puerarin in human plasma by high performance liquid chromatography.

Zhongze Ma1, Qingli Wu, David Y W Lee, Michael Tracy, Scott E Lukas.   

Abstract

Puerarin, an isoflavone C-glycoside, has been identified as the major active component isolated from Pueraria lobata (Kudzu) responsible for suppression of alcohol drinking. In order to conduct clinical studies of Kudzu's efficacy, a method for measuring its bioavailability and pharmacokinetic profile is needed. We have developed a gradient reversed-phase HPLC system for pharmacokinetic study of puerarin in human plasma. Solid-phase extraction was performed on an abselut Nexus cartridge (60 mg/3 ml) possessing adsorbent function with a recovery of >97% and 4-hydroxybenzoic acid was used as an internal standard. The HPLC assay was performed on a YMC ODS-A column (150 mm x 4.6mm i.d., 5 microm particle size). The HPLC mobile phase consisted of methanol/0.5% acetic acid with 20-35% methanol gradient at a flow-rate of 0.8 ml/min. The UV wavelength was set at 254 nm. Calibration of the overall analytical procedure gave a linear signal (r>0.999) over a puerarin concentration range of 5-500 ng/ml in human plasma. The lower limit of quantification was ca. at 8 ng/ml of puerarin in plasma. The detection limit (defined as signal-to-noise ratio of about 3) was approximately 3 ng/ml. The preliminary pharmacokinetic study after oral administration of the Kudzu capsules containing 400mg of puerarin to a healthy volunteer confirmed that the present method was suitable for determining puerarin in human plasma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16009605     DOI: 10.1016/j.jchromb.2005.06.016

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Development of an enzyme-linked immunosorbent assay to determine puerarin and its aglycone daidzein.

Authors:  Benyakarn Pongkitwitoon; Seiichi Sakamoto; Hiroyuki Tanaka; Ryota Tsuchihashi; Junei Kinjo; Satoshi Morimoto; Waraporn Putalun
Journal:  J Nat Med       Date:  2010-07-24       Impact factor: 2.343

2.  A standardized kudzu extract (NPI-031) reduces alcohol consumption in nontreatment-seeking male heavy drinkers.

Authors:  Scott E Lukas; David Penetar; Zhaohui Su; Thomas Geaghan; Melissa Maywalt; Michael Tracy; John Rodolico; Christopher Palmer; Zhongze Ma; David Y-W Lee
Journal:  Psychopharmacology (Berl)       Date:  2012-10-16       Impact factor: 4.530

3.  hVMAT2: A Target of Individualized Medication for Parkinson's Disease.

Authors:  Nian Xiong; Nuomin Li; Eden Martin; Jinlong Yu; Jie Li; Jing Liu; David Yue-Wei Lee; Ole Isacson; Jeffery Vance; Hong Qing; Tao Wang; Zhicheng Lin
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

4.  MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate.

Authors:  Qi Liu; Changyuan Wang; Qiang Meng; Xiaokui Huo; Huijun Sun; Jinyong Peng; Xiaochi Ma; Pengyuan Sun; Kexin Liu
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

5.  The isoflavone puerarin reduces alcohol intake in heavy drinkers: a pilot study.

Authors:  David M Penetar; Lindsay H Toto; Stacey L Farmer; David Y-W Lee; Zhongze Ma; Yanze Liu; Scott E Lukas
Journal:  Drug Alcohol Depend       Date:  2012-05-10       Impact factor: 4.492

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.